SB16 versus reference denosumab in postmenopausal women with osteoporosis: 18-month outcomes of a phase III randomized clinical trial
Switching from DEN to SB16 demonstrated comparable efficacy, safety, PD, PK, and immunogenicity in PMO patients relative to those who continued DEN. SB16 was well tolerated over 18 months, demonstrating comparable outcomes to DEN.
Authors
- Yoon‐Sok Chung (ORCID: https://orcid.org/0000-0003-0179-4386)
- J. Bán (ORCID: https://orcid.org/0009-0008-0786-5994)
- Rafał Sapuła
- Eva Dokoupilová
- Ki‐Hyun Baek (ORCID: https://orcid.org/0000-0002-4097-1077)
- Rafal Plebanski
- Audrone Urboniene
- J. Rosa (ORCID: https://orcid.org/0000-0001-7807-7751)
- Robert Mordaka
- Richard Eastell (ORCID: https://orcid.org/0000-0002-0323-3366)
- Anna Rowińska-Osuch
- Young Hee Rho
- Bente Lomholdt Langdahl (ORCID: https://orcid.org/0000-0002-8712-7199)
- E. J. Czerwiński (ORCID: https://orcid.org/0000-0002-2564-7658)
- Sohui Ahn
- Andrzej Mydlak
- Jerzy Supronik
Institutions
- Masaryk University (CZ)
- Samsung (South Korea) (KR)
- University of Siedlce (PL)
- Aarhus University Hospital (DK)
- Hospital of Lithuanian University of Health Sciences Kaunas Clinics (LT)
- University of Management and Administration in Zamosc (PL)
- The Catholic University of Korea Yeouido St. Mary's Hospital (KR)
- Affidea (CH)
- Centrum Medyczne iMed24 (PL)
- Medical Plus (CZ)
- Łukasiewicz Research Network (PL)
- State Higher School of Vocational Education in Zamość (PL)
- Ajou University (KR)
- University of Sheffield (GB)
Publication Details
- Journal
- Bone
- Published
- 2024-12-13
- DOI
- https://doi.org/10.1016/j.bone.2024.117371
- Citations
- 5
- Primary Topic
- Bone health and osteoporosis research
- Type
- article
- Field-Weighted Citation Impact
- 2.39